Breakthrough Medicines for treatment of Cancer and Inflammatory diseases

PROGRAMS

Program

Indication

Partner

TARGET TO HIT

HIT TO LEAD

LEAD OPTIMIZATION

CANDIDATE/IND

PHASE I

RORγt Inhibitor
Dermatology, Psoriatic arthritis
Candidate Selection
RORγt Inhibitor
Other
Preclinical
BRD (BD1)
Inflammation
Lead optimization
Cytokine X
Inflammation
Hit-to-lead
RORγt Agonist
Immuno-oncology
Hit-to-lead
GRP78
Oncology
Hit-to-lead
10+ Research programs
Screening

RESEARCH COLLABORATIONS

Program

Indication

Partner

TARGET TO HIT

HIT TO LEAD

LEAD OPTIMIZATION

CANDIDATE/IND

PHASE I

Multi-target
Oncology, CNS
Hit-to-lead
Contract research
Oncology, Inflammation, Infectious diseases
Discovery
NSD1/2/3
Hematological cancers
Discovery